Emerald Advisers, LLC Chemo Centryx, Inc. Transaction History

Emerald Advisers, LLC

$2.41 Billion
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Jul 29, 2021	SELL	$9.59 - $50.88 $2.06 Million - $10.9 Million	-214,672 Closed	0 $0
Q1 2021 Apr 29, 2021	SELL	$49.53 - $68.4 $12.3 Million - $17.1 Million	-249,289 Reduced 53.73%	214,672 $11 Million
Q4 2020 Jan 29, 2021	BUY	$47.25 - $65.16 $3.73 Million - $5.14 Million	78,855 Added 20.48%	463,961 $28.7 Million
Q3 2020 Oct 28, 2020	SELL	$46.35 - $61.69 $775,574 - $1.03 Million	-16,733 Reduced 4.16%	385,106 $21.1 Million
Q2 2020 Jul 28, 2020	BUY	$38.58 - $65.07 $1.05 Million - $1.76 Million	27,105 Added 7.23%	401,839 $23.1 Million
Q1 2020 Apr 30, 2020	BUY	$32.73 - $50.78 $6.6 Million - $10.2 Million	201,514 Added 116.33%	374,734 $15.1 Million
Q4 2019 Jan 29, 2020	BUY	$6.81 - $39.55 $1.18 Million - $6.85 Million	173,220 New	173,220 $6.85 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Emerald Advisers, LLC with notifications on news.